- Report
- February 2021
Global
From €2846EUR$2,960USD£2,442GBP
- Report
- March 2021
- 52 Pages
Global
From €3841EUR$3,995USD£3,295GBP
- Report
- March 2021
- 132 Pages
Global
From €10572EUR$10,995USD£9,069GBP
- Report
- May 2019
- 49 Pages
Global
From €3361EUR$3,495USD£2,883GBP
- Drug Pipelines
- November 2020
- 575 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- August 2023
- 93 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Report
- September 2022
- 490 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- November 2021
- 620 Pages
Global
From €3846EUR$4,000USD£3,299GBP
- Report
- October 2022
- 290 Pages
Global
From €5510EUR$5,730USD£4,727GBP
The Hepatitis B Drug market is a subset of the Infectious Diseases Drugs market. It is composed of drugs used to treat the hepatitis B virus, a virus that can cause serious liver damage. These drugs are used to reduce the amount of virus in the body, reduce the risk of liver damage, and improve overall health. Common drugs used to treat hepatitis B include interferon, nucleoside analogues, and protease inhibitors.
The Hepatitis B Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Gilead Sciences, Merck & Co., AbbVie, Bristol-Myers Squibb, and GlaxoSmithKline. Show Less Read more
